BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2024

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

	Three Month Period Ended:
	March 31,		March 31,
	2024		2023
Research and development services (over-time)	$	65,200	$	87,907
Clinical laboratory testing services (point-in-time)		6,440		3,003,022
Clinical laboratory testing services (over-time)		324,580		938,080
Product and authentication services (point-in-time):
Supply chain		275,259		27,636
Large Scale DNA Production		258,152		253,626
Asset marking		—		97,343
Total	$	929,631	$	4,407,614

	Six Month Period Ended:
	March 31,		March 31,
	2024		2023
Research and development services (over-time)	$	142,735	$	213,964
Clinical laboratory testing services (point-in-time)		18,560		6,077,436
Clinical laboratory testing services (over-time)		649,160		2,377,961
Product and authentication services (point-in-time):
Supply chain		742,746		439,973
Large Scale DNA Production		258,152		381,131
Asset marking		9,442		179,901
Total	$	1,820,795	$	9,670,366

Schedule of opening and closing contract balances

		October 1,		March 31,		$
	Balance sheet classification	2023		2024		change
Contract liabilities	Deferred revenue	$	270,435	$	245,285	$	25,150

Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows

	March 31,		September 30,
	2024		2023
Cash and cash equivalents	$	3,149,640	$	7,151,800
Restricted cash		750,000		750,000
Total cash, cash equivalents and restricted cash	$	3,899,640	$	7,901,800

Schedule of anti-dilutive securities not included computation of net loss per share

Securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and six-month periods ended March  31, 2024 and 2023 are as follows:

	2024	2023
Warrants	825,066	364,779
Restricted Stock Units	—	14,132
Stock options	109,363	110,317
Total	934,429	489,228